Back

The kinase activity of the cancer stem cell marker DCLK1 drives gastric cancer progression by reprogramming the stromal tumor landscape

Afshar-Sterle, S.; Carli, A. L. E.; O'Keefe, R.; Tse, J.; Fischer, S.; Azimpour, A. I.; Baloyan, D.; Elias, L.; Thilakasiri, P.; Patel, O.; Ferguson, F. M.; Eissmann, M. F.; Chand, A. L.; Gray, N. S.; Busuttil, R.; Boussioutas, A.; Lucet, I.; Ernst, M.; Buchert, M.

2022-04-21 cancer biology
10.1101/2022.04.21.489109 bioRxiv
Show abstract

Gastric cancer (GC) is the 3rd leading cause of cancer mortality worldwide, therefore providing novel diagnostic and treatment options is crucial for at risk groups. The serine/threonine kinase doublecortin-like kinase 1 (DCLK1) is a proposed driver of GC with frequent amplification and somatic missense mutations yet the molecular mechanism how DCLK1 mediates tumorigenesis is poorly understood. We report how DCLK1 expression orchestrates complementary cancer cell intrinsic and extrinsic processes leading to a comprehensive pro-invasive and pro-metastatic reprogramming of cancer cells and tumor stroma in a DCLK1 kinase-dependent manner. Mechanistically, we identify the chemokine CXCL12 as a key promoter of the pro-tumorigenic properties downstream of DCLK1. Importantly, inhibition of the DCLK1 kinase domain reverses the pro-tumorigenic and pro-metastatic phenotype. Together, this study establishes DCLK1 as a promising, targetable master regulator of GC. TeaserDCLK1 is a druggable cancer driver of GC

Matching journals

The top 14 journals account for 50% of the predicted probability mass.

1
Cancers
○ 213 papers in training set
Top 0.8%
6.6%
Similar papers in this journal
2
JCI Insight
● 277 papers in training set
Top 0.8%
6.6%
Similar papers in this journal
3
Cancer Research
● 130 papers in training set
Top 0.8%
4.7%
Similar papers in this journal
4
Cancer Discovery
● 66 papers in training set
Top 0.6%
4.2%
Similar papers in this journal
5
eLife
● 5828 papers in training set
Top 31%
4.0%
Similar papers in this journal
6
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 15%
3.4%
7
Oncogene
○ 85 papers in training set
Top 0.6%
3.2%
8
Clinical Cancer Research
● 64 papers in training set
Top 0.7%
3.2%
9
Journal of Clinical Investigation
● 179 papers in training set
Top 2%
3.2%
10
Cancer Letters
○ 35 papers in training set
Top 0.2%
3.2%
11
Molecular Cancer Research
● 49 papers in training set
Top 0.4%
2.7%
12
EMBO Molecular Medicine
○ 95 papers in training set
Top 0.4%
2.6%
13
Molecular Oncology
○ 55 papers in training set
Top 0.4%
2.6%
14
Frontiers in Oncology
○ 103 papers in training set
Top 1%
2.4%
50% of probability mass above
15
Nature Communications
○ 5641 papers in training set
Top 40%
2.4%
16
Journal for ImmunoTherapy of Cancer
● 75 papers in training set
Top 0.9%
2.3%
17
British Journal of Cancer
○ 49 papers in training set
Top 0.5%
2.3%
18
Cellular and Molecular Gastroenterology and Hepatology
○ 46 papers in training set
Top 0.5%
2.1%
19
Science Advances
● 1243 papers in training set
Top 20%
1.7%
20
OncoImmunology
○ 24 papers in training set
Top 0.4%
1.7%
21
Journal of Experimental Medicine
● 119 papers in training set
Top 2%
1.7%
22
The Journal of Pathology
○ 26 papers in training set
Top 0.4%
1.7%
23
Journal of Experimental & Clinical Cancer Research
○ 25 papers in training set
Top 0.4%
1.5%
24
Cancer Cell
○ 42 papers in training set
Top 0.9%
1.4%
25
NAR Cancer
◐ 37 papers in training set
Top 0.4%
1.3%
26
Cell Reports Medicine
○ 153 papers in training set
Top 3%
1.3%
27
Cell Reports
○ 1498 papers in training set
Top 22%
1.3%
28
Molecular Cancer Therapeutics
● 40 papers in training set
Top 0.7%
1.1%
29
Cancer Immunology Research
● 35 papers in training set
Top 0.7%
1.1%
30
Cell Death & Disease
147 papers in training set
Top 3%
1.1%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.